|
|
|
|
|
Bleomycin
drug data and news
Bleomycin drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Bleomycin | ||
| Brand Names/Synonyms | BLEOMYCIN; BLM; Blenoxane; Bleo; Bleocin; Bleomicin; Bleomicina [INN-Spanish]; Bleomycin (USAN ); Bleomycin sulfate; Bleomycine [INN-French]; Bleomycins; Bleomycinum [INN-Latin] | ||
| Indication | For palliative treatment in the management of the following neoplasms; Malignant neoplasm (trachea, bronchus, lung); Squamous cell carcinoma; Lymphomas | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Bleomycin is an antibiotic which has been shown to have antitumor activity. Bleomycin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. Bleomycin has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2. The antibiotic antitumor drugs are cell cycle-nonspecific except for Bleomycin (which has major effects in G2 and M phases). Bleomycin is indicated in the palliative treatment of squamous cell carcinoma, lymphomas, testicular carcinoma, alone or in combination with other drugs. | ||
| Mechanism Of Action | Although the exact mechanism of action of Bleomycin is unknown, available evidence would seem to indicate that the main mode of action is the inhibition of DNA synthesis with some evidence of lesser inhibition of RNA and protein synthesis. | ||
| Bleomycin News (When available) |
Cancer Consultants (press release), ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) is the most commonly used chemotherapy regimen. BEACOPP (bleomycin, etoposide ... Patients with Unfavorable Risk Hodgkin’s Lymphoma May Not ... Dec 20, 2005 Cancer Consultants (press release), ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) is the most commonly used chemotherapy regimen for Hodgkin’s lymphoma. ... PhotoCure ASA - PCI technology enhances effect of anti-cancer drug Dec 5, 2005 Biotech Intelligence (press release), ...journal Clinical Cancer Research, it is now demonstrated that PCI can significantly improve the curative effect of the anti-cancer drug bleomycin in animal ... Intensive Chemotherapy Regimen Shows Promise for Germ Cell Tumors Dec 5, 2005 Cancer Consultants (press release), This regimen consisted of cycles of cisplatin, vincristine, bleomycin, and carboplatin, followed by one cycle of vincristin and bleomycin and three cycles of ... Role of Eotaxin-1 (CCL11) and CC Chemokine Receptor 3 (CCR3) in ... Dec 9, 2005 Am J Pathology (subscription) The present study examined the pulmonary expression of CCL11 and CCR3 during bleomycin (blm)-induced lung injury and determined their importance in the ... Plenary Session Snapshot Dec 19, 2005 Medscape (subscription) And, as discussed in the session, the results of chemo-radiation using a limited number of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine), commonly ... | ||
| Dosage Forms | Injection; POWDER FOR SOLUTION | ||
| Drug_Category | Antimetabolites; Antibiotics; Antineoplastic Agents; ATC:L01DC01 | ||
| Absorption | systemic absorption approximately 45% | ||
| Interactions | [an error occurred while processing this directive] | ||
| Toxicity | Excessive exposure may cause fever, chills, nausea, vomiting, mental, confusion, and wheezing. Bleomycin may cause irritation to eyes, skin and respiratory tract. It may also cause a darkening or thickening of the skin. It may cause an allergic reaction. | ||
| Organisms Affected | Not Available | ||
| Chemical IUPAC Name | 3-[[2-[2-[2-[2-[4-[2-[6-amino-2-[1-(2-amino-2-carbamoyl-ethyl)amino-2-carbamoyl-ethyl]-5-methyl-pyrimidin-4-yl]carbonylamino-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-3-(3H-imidazol-4-yl)propanoyl]amino-3-hydroxy-2-methyl-pentanoyl]amino-3-hydroxy-butanoyl]aminoethyl]-1,3-thiazol-4-yl]-1,3-thiazol-4-yl]carbonylamino]propyl-dimethyl-sulfonium | ||
| Chemical Formula | C55H84N17O21S3 | ||
| Molecular Weight | 1415.56 g/mol | ||
| Smiles String | CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O | ||
| Melting Point | Approx 160 F | ||
| Water Solubility | Soluble | ||
| State | Colorless or yellowish powder which becomes bluish depending on Cu content. | ||
| LogP/Hphobicity | Not Available | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | hepatic | ||
| Half Life | 115 minutes | ||
| Protein Binding [%] | 1% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Bleomycin.html http://www.rxlist.com/cgi/generic3/bleomycin.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00453 | ||
| CAS Registry Number | 11056-06-7 | ||
| KEGG Compound ID | C06854 | ||
| PubChem ID | SID:602743 | ||
| PharmGKB ID | PA448645 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2131692 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |